PH12021552513A1 - Pyrrole compounds - Google Patents
Pyrrole compoundsInfo
- Publication number
- PH12021552513A1 PH12021552513A1 PH1/2021/552513A PH12021552513A PH12021552513A1 PH 12021552513 A1 PH12021552513 A1 PH 12021552513A1 PH 12021552513 A PH12021552513 A PH 12021552513A PH 12021552513 A1 PH12021552513 A1 PH 12021552513A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutically acceptable
- pyrrole compounds
- formula
- methods
- acceptable salts
- Prior art date
Links
- 150000003233 pyrroles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828919P | 2019-04-03 | 2019-04-03 | |
| US201962932686P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/026116 WO2020205934A1 (en) | 2019-04-03 | 2020-04-01 | Pyrrole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552513A1 true PH12021552513A1 (en) | 2022-10-03 |
Family
ID=72667046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552513A PH12021552513A1 (en) | 2019-04-03 | 2020-04-01 | Pyrrole compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11191747B2 (https=) |
| EP (2) | EP4733305A2 (https=) |
| JP (3) | JP7627008B2 (https=) |
| KR (2) | KR20260036605A (https=) |
| CN (4) | CN121108187A (https=) |
| AU (2) | AU2020253444C1 (https=) |
| BR (1) | BR112021019817A2 (https=) |
| CA (1) | CA3134635A1 (https=) |
| CL (1) | CL2021002575A1 (https=) |
| CO (1) | CO2021014210A2 (https=) |
| DK (1) | DK3947349T3 (https=) |
| FI (1) | FI3947349T3 (https=) |
| GE (2) | GEP20257772B (https=) |
| IL (1) | IL286902B2 (https=) |
| MA (1) | MA55564A (https=) |
| MX (1) | MX2021012105A (https=) |
| PE (1) | PE20220252A1 (https=) |
| PH (1) | PH12021552513A1 (https=) |
| SG (1) | SG11202110718PA (https=) |
| TW (1) | TWI846853B (https=) |
| UA (1) | UA129029C2 (https=) |
| WO (1) | WO2020205934A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121108187A (zh) | 2019-04-03 | 2025-12-12 | 阿里戈斯治疗公司 | 吡咯化合物 |
| CN114685514A (zh) * | 2020-12-29 | 2022-07-01 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的应用 |
| WO2022156758A1 (zh) * | 2021-01-22 | 2022-07-28 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的用途 |
| CA3231695A1 (en) | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| CN118974014B (zh) * | 2022-03-17 | 2026-01-27 | 成都微芯药业有限公司 | 吡咯酰胺类化合物及其制备方法和用途 |
| CN116120219A (zh) * | 2022-12-27 | 2023-05-16 | 吉斯凯(苏州)制药有限公司 | 一种多取代吡咯类化合物及其制备方法和在制备hbv衣壳蛋白抑制剂中的应用 |
| JP2026503674A (ja) * | 2023-01-26 | 2026-01-29 | アリゴス セラピューティクス インコーポレイテッド | Ｂ型肝炎併用療法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4784782A (en) | 1986-03-27 | 1988-11-15 | The Lubrizol Corporation | Heterocyclic compounds useful as additives for lubricant and fuel compositions |
| BR0112826A (pt) | 2000-07-17 | 2003-06-24 | Ranbaxy Lab Ltd | Derivados da oxazolidinona como antimicrobianos |
| EP1389209B1 (en) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| US6956040B2 (en) | 2001-07-16 | 2005-10-18 | Ranbaxy Laboratories Limited | Oxazolidinone piperazinyl derivatives as potential antimicrobials |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| ZA200505523B (en) | 2002-12-20 | 2006-09-27 | Amgen Inc | Asthma and allergic inflammation modulators |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| GB2398299A (en) | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
| US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| AU2005221959C1 (en) | 2004-03-13 | 2010-06-17 | Kyoto University | Novel indole derivative for alkylating specific base sequence of DNA and alkylating agent and drug each comprising the same |
| US20060102471A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer |
| US20060105355A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer having a linker moiety |
| US8835476B2 (en) | 2005-03-04 | 2014-09-16 | Fan Wu | Synthesis of novel antimicrobials |
| US20100234379A1 (en) | 2005-07-28 | 2010-09-16 | Bahr Ben A | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity |
| US20070065877A1 (en) | 2005-09-19 | 2007-03-22 | Combimatrix Corporation | Microarray having a base cleavable succinate linker |
| KR101507375B1 (ko) | 2006-09-15 | 2015-04-07 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | 키나아제 억제제 화합물 |
| EP2155720B1 (en) | 2007-06-08 | 2013-07-17 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| CN101679358B (zh) | 2007-06-18 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的吡咯衍生物 |
| CA2754492A1 (en) | 2009-03-05 | 2010-09-10 | Purdue Research Foundation | Method for early imaging of atherosclerosis |
| WO2010107736A2 (en) | 2009-03-20 | 2010-09-23 | University Of Virginia Patent Foundation | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials |
| BR112012009576A2 (pt) | 2009-10-22 | 2019-09-24 | Univ Vanderbilt | potencializador alostérico de mglur4, composições, e métodos de tratamento de disfunção neurológica |
| BR112012028894A2 (pt) | 2010-05-12 | 2019-09-24 | Univ Vanderbilt | sulfona heterocíclica como potenciadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica |
| KR20130087495A (ko) | 2010-06-15 | 2013-08-06 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 안트라닐산 유도체 |
| MX2013002895A (es) | 2010-09-14 | 2013-06-05 | Inst Biochemii I Biofizyki Pan | Compuestos como moduladores de una proteina cftr mutante y su uso para tratar enfermedades asociadas con las deficiencias de la proteina cftr. |
| WO2012047525A2 (en) | 2010-09-27 | 2012-04-12 | Endocyte, Inc. | Folate conjugates for treating inflammation of the eye |
| WO2012078902A2 (en) | 2010-12-08 | 2012-06-14 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US20130072473A1 (en) | 2011-05-09 | 2013-03-21 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
| WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| DK2707101T3 (da) | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| EP3085368A1 (en) | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| US8835640B1 (en) | 2011-11-16 | 2014-09-16 | Paresh T. Gandhi | Nicotine derivatives |
| HK1210969A1 (en) | 2012-01-20 | 2016-05-13 | 奥克塞拉有限公司 | Substituted heterocyclic compounds for disease treatment |
| EP3345597A3 (en) | 2012-09-19 | 2018-08-22 | Faller & Williams Technology, LLC | Pkc delta inhibitors for use as therapeutics |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| DK3024819T3 (en) * | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| CN104672221B (zh) | 2013-11-29 | 2018-01-23 | 中国科学院上海有机化学研究所 | 一种氟代苯并杂环‑杂芳环结构的合成方法 |
| US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
| KR101726059B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 암모늄 염을 포함하는 브롬화수소 가스 검출용 조성물 및 이를 포함하는 브롬화수소 가스 검출용 색변환 센서 |
| KR101726060B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 금속 염을 포함하는 염화수소 가스 검출용 조성물 및 이를 포함하는 염화수소 가스 검출용 색변환 센서 |
| WO2017081615A1 (en) | 2015-11-09 | 2017-05-18 | Wockhardt Limited | 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections |
| US10752584B2 (en) * | 2016-03-09 | 2020-08-25 | Emory University | Elimination of hepatitis B virus with antiviral agents |
| JOP20190024A1 (ar) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108250121A (zh) | 2016-12-28 | 2018-07-06 | 上海长森药业有限公司 | 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途 |
| CN115974753A (zh) | 2018-03-30 | 2023-04-18 | 正大天晴药业集团股份有限公司 | 含有n杂五元环化合物和用途 |
| BR112021006403A2 (pt) | 2018-10-05 | 2021-07-06 | Univ Emory | agentes monômeros e multiméricos anti-hbv |
| MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
| CN121108187A (zh) | 2019-04-03 | 2025-12-12 | 阿里戈斯治疗公司 | 吡咯化合物 |
| AU2020385034B2 (en) | 2019-11-13 | 2024-11-14 | Xi'an Xintong Pharmaceutical Research Co., Ltd. | HBV inhibitor and use thereof |
| CN114685514A (zh) | 2020-12-29 | 2022-07-01 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的应用 |
-
2020
- 2020-04-01 CN CN202511435986.XA patent/CN121108187A/zh active Pending
- 2020-04-01 WO PCT/US2020/026116 patent/WO2020205934A1/en not_active Ceased
- 2020-04-01 EP EP26163262.4A patent/EP4733305A2/en active Pending
- 2020-04-01 FI FIEP20784496.0T patent/FI3947349T3/fi active
- 2020-04-01 DK DK20784496.0T patent/DK3947349T3/da active
- 2020-04-01 CN CN202511436317.4A patent/CN121085825A/zh active Pending
- 2020-04-01 GE GEAP202015762A patent/GEP20257772B/en unknown
- 2020-04-01 CA CA3134635A patent/CA3134635A1/en active Pending
- 2020-04-01 GE GEAP202515762A patent/GEAP202515762A/en unknown
- 2020-04-01 US US16/837,515 patent/US11191747B2/en active Active
- 2020-04-01 PE PE2021001658A patent/PE20220252A1/es unknown
- 2020-04-01 PH PH1/2021/552513A patent/PH12021552513A1/en unknown
- 2020-04-01 IL IL286902A patent/IL286902B2/en unknown
- 2020-04-01 MX MX2021012105A patent/MX2021012105A/es unknown
- 2020-04-01 CN CN202511330314.2A patent/CN121108034A/zh active Pending
- 2020-04-01 TW TW109111398A patent/TWI846853B/zh active
- 2020-04-01 SG SG11202110718PA patent/SG11202110718PA/en unknown
- 2020-04-01 KR KR1020267006069A patent/KR20260036605A/ko active Pending
- 2020-04-01 MA MA055564A patent/MA55564A/fr unknown
- 2020-04-01 CN CN202080028131.4A patent/CN114258391A/zh active Pending
- 2020-04-01 BR BR112021019817A patent/BR112021019817A2/pt unknown
- 2020-04-01 JP JP2021559054A patent/JP7627008B2/ja active Active
- 2020-04-01 AU AU2020253444A patent/AU2020253444C1/en active Active
- 2020-04-01 KR KR1020217035886A patent/KR102933784B1/ko active Active
- 2020-04-01 UA UAA202105907A patent/UA129029C2/uk unknown
- 2020-04-01 EP EP20784496.0A patent/EP3947349B1/en active Active
-
2021
- 2021-10-01 CL CL2021002575A patent/CL2021002575A1/es unknown
- 2021-10-25 CO CONC2021/0014210A patent/CO2021014210A2/es unknown
- 2021-11-16 US US17/455,178 patent/US11771680B2/en active Active
-
2023
- 2023-08-22 US US18/453,887 patent/US12599582B2/en active Active
-
2024
- 2024-06-25 JP JP2024101773A patent/JP7710215B2/ja active Active
-
2025
- 2025-06-30 JP JP2025110439A patent/JP7811768B2/ja active Active
- 2025-08-13 AU AU2025217289A patent/AU2025217289A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2024000299A (es) | Compuestos antivirales. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12022553378A1 (en) | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| ZA202204442B (en) | Salt forms of a complement component c5a receptor | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| MX2021009717A (es) | Sulfonamidas biciclicas. | |
| SG11201907945YA (en) | Azetidine derivative | |
| AU2019296118A8 (en) | Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor | |
| ZA202400679B (en) | Dimethyl-substituted thiazololactam compound and use thereof | |
| MA67325B1 (fr) | Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble | |
| PH12021550323A1 (en) | Dendrimer formulations | |
| WO2021015294A3 (en) | Combination therapy for cancer treatment | |
| MY208423A (en) | Composition of aminopyran derivative |